U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2017
411
Name Type Language
OCRELIZUMAB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
OCREVUS
Preferred Name English
RG-1594
Code English
OCRELIZUMAB [MI]
Common Name English
OCRELIZUMAB [USAN]
Common Name English
Ocrelizumab [WHO-DD]
Common Name English
OCRELIZUMAB [PURPLE BOOK CDER]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD20 (ANTIGEN)) (HUMAN-MOUSE MONOCLONAL 2H7 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2H7 .KAPPA.-CHAIN, DIMER
Common Name English
OCRELIZUMAB [JAN]
Common Name English
ocrelizumab [INN]
Common Name English
PR-070769
Code English
PR070769
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD20 (ANTIGEN)) (HUMAN-MOUSE MONOCLONAL 2H7 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL 2H7 .KAPPA.-CHAIN, DIMER
Common Name English
R-1594
Code English
Classification Tree Code System Code
NCI_THESAURUS C20401
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
NDF-RT N0000175657
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
NCI_THESAURUS C574
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
WHO-ATC L04AA36
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
Code System Code Type Description
CAS
637334-45-3
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
INN
8636
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
LACTMED
Ocrelizumab
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
ChEMBL
CHEMBL2108041
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
USAN
QQ-93
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
DAILYMED
A10SJL62JY
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
RXCUI
1876366
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
SMS_ID
100000144876
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
EVMPD
SUB121707
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
DRUG CENTRAL
5223
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
DRUG BANK
DB11988
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
WIKIPEDIA
Ocrelizumab
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
NCI_THESAURUS
C66250
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
MERCK INDEX
m12020
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
FDA UNII
A10SJL62JY
Created by admin on Mon Mar 31 18:19:45 GMT 2025 , Edited by admin on Mon Mar 31 18:19:45 GMT 2025
PRIMARY
ACTIVE MOIETY
OCRELIZUMAB
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966